KCa3.1 inhibition switches the phenotype of glioma-infiltrating microglia/macrophages

Autor: Grimaldi, A, D'Alessandro, G, Golia, MT, Grössinger, EM, Di Angelantonio, S, Ragozzino, D, Santoro, A, Esposito, V, Wulff, H, Catalano, M, Limatola, C

Publikováno v: Cell death & disease, vol 7, iss 4

Among the strategies adopted by glioma to successfully invade the brain parenchyma is turning the infiltrating microglia/macrophages (M/MΦ) into allies, by shifting them toward an anti-inflammatory, pro-tumor phenotype. Both glioma and infiltrating

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::e634e1efba310fb6eb5a8a6807be5569
https://escholarship.org/uc/item/9sk57313

Ca ²⁺ -Dependent Regulation of NFATc1 via KCa3.1 in Inflammatory Osteoclastogenesis.

Autor: Grössinger EM; Division of Rheumatology, Allergy, and Clinical Immunology, Department of Internal Medicine, University of California Davis, Davis, CA 95616., Kang M; Division of Rheumatology, Allergy, and Clinical Immunology, Department of Internal Medicine, University of California Davis, Davis, CA 95616., Bouchareychas L; Division of Rheumatology, Allergy, and Clinical Immunology, Department of Internal Medicine, University of California Davis, Davis, CA 95616., Sarin R; Division of Rheumatology, Allergy, and Clinical Immunology, Department of Internal Medicine, University of California Davis, Davis, CA 95616., Haudenschild DR; Center for Musculoskeletal Health, University of California Davis, Sacramento, CA 95817., Borodinsky LN; Department of Physiology and Membrane Biology, University of California Davis, Davis, CA 95616; and.; Institute for Pediatric Regenerative Medicine, Shriners Hospital for Children - Northern California, Sacramento, CA 95817., Adamopoulos IE; Division of Rheumatology, Allergy, and Clinical Immunology, Department of Internal Medicine, University of California Davis, Davis, CA 95616; iannis@ucdavis.edu.; Institute for Pediatric Regenerative Medicine, Shriners Hospital for Children - Northern California, Sacramento, CA 95817.

Publikováno v: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2018 Jan 15; Vol. 200 (2), pp. 749-757. Date of Electronic Publication: 2017 Dec 15.

Differential Kv1.3, KCa3.1, and Kir2.1 expression in "classically" and "alternatively" activated microglia.

Autor: Nguyen HM; Department of Pharmacology, University of California, Davis, California., Grössinger EM; Department of Pharmacology, University of California, Davis, California., Horiuchi M; Department of Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, California.; M.I.N.D. Institute, University of California Davis Medical Center, Davis, Sacramento, California., Davis KW; Department of Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, California., Jin LW; Department of Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, California.; M.I.N.D. Institute, University of California Davis Medical Center, Davis, Sacramento, California., Maezawa I; Department of Pathology and Laboratory Medicine, University of California Davis Medical Center, Sacramento, California.; M.I.N.D. Institute, University of California Davis Medical Center, Davis, Sacramento, California., Wulff H; Department of Pharmacology, University of California, Davis, California.

Publikováno v: Glia [Glia] 2017 Jan; Vol. 65 (1), pp. 106-121. Date of Electronic Publication: 2016 Oct 03.

KCa3.1 inhibition switches the phenotype of glioma-infiltrating microglia/macrophages.

Autor: Grimaldi A; Department of Physiology and Pharmacology, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy., D'Alessandro G; Department of Physiology and Pharmacology, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.; IRCCS Neuromed, Via Atinense 18, Pozzilli 86077, Italy., Golia MT; Department of Physiology and Pharmacology, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy., Grössinger EM; Department of Pharmacology, University of California, 451 Health Sciences Drive, GBSF3502, Davis, CA 95616, USA., Di Angelantonio S; Department of Physiology and Pharmacology, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.; Center for Life Nanoscience Istituto Italiano di Tecnologia@Sapienza, Rome, Italy., Ragozzino D; Department of Physiology and Pharmacology, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.; IRCCS Neuromed, Via Atinense 18, Pozzilli 86077, Italy., Santoro A; Department of Neurology and Psychiatry, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy., Esposito V; IRCCS Neuromed, Via Atinense 18, Pozzilli 86077, Italy.; Department of Neurology and Psychiatry, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy., Wulff H; Department of Pharmacology, University of California, 451 Health Sciences Drive, GBSF3502, Davis, CA 95616, USA., Catalano M; Department of Physiology and Pharmacology, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.; IRCCS Neuromed, Via Atinense 18, Pozzilli 86077, Italy., Limatola C; IRCCS Neuromed, Via Atinense 18, Pozzilli 86077, Italy.; Pasteur Institute-Department of Physiology and Pharmacology, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185, Italy.

Publikováno v: Cell death & disease [Cell Death Dis] 2016 Apr 07; Vol. 7, pp. e2174. Date of Electronic Publication: 2016 Apr 07.

Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade.

Autor: Grössinger EM; 1] Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria [2] Department of Cell Biology, University of Salzburg, Salzburg, Austria., Weiss L; Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria., Zierler S; Walther-Straub-Institute for Pharmacology and Toxicology, Ludwig-Maximilians-University Munich, Munich, Germany., Rebhandl S; Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria., Krenn PW; Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria., Hinterseer E; Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria., Schmölzer J; Department of Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, Austria., Asslaber D; Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria., Hainzl S; Division of Experimental Dermatology and EB House Austria, Department of Dermatology, Paracelsus Medical University, Salzburg, Austria., Neureiter D; Department of Pathology, Paracelsus Medical University, Salzburg, Austria., Egle A; Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria., Piñón-Hofbauer J; Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria., Hartmann TN; Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria., Greil R; Laboratory for Immunological and Molecular Cancer Research (LIMCR), Third Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria., Kerschbaum HH; Department of Cell Biology, University of Salzburg, Salzburg, Austria.

Publikováno v: Leukemia [Leukemia] 2014 Apr; Vol. 28 (4), pp. 954-8. Date of Electronic Publication: 2014 Jan 20.